Prestige BioPharma first-in-class pancreatic cancer treatment receives France clinical trial approval
KUALA LUMPUR: Prestige BioPharma Limited (PBP) announced that French National Agency for the Safety of Medicines and Health Products has approved a Phase 1/2a clinical trial of its first-in-class anti-PAUF monoclonal antibody, PBP1510, for pancreatic cancer treatment. The trial will be conducted in the Research Institute against Digestive Cancer (IRCAD) based in Strasbourg, France, in […]